The Remain-1 trial will enrol patients on tirzepatide who have lost at least 15% in total body weight. Credit: grinny via Shutterstock.

US-based biotech Fractyl Health has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to conduct a clinical trial of its Revita endoscopy system, the same day it announced a $19.2m net loss in the company’s most recent quarter. 

Revita is an outpatient endoscopic technique focused on the duodenum, the first part of the small intestine. It is designed to address the underlying issues in the duodenal lining that contribute to obesity and type 2 diabetes (T2D).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The system obtained CE approval in Europe and was granted reimbursement authorisation for T2D treatment via NUB in Germany in 2022. 

The Remain-1 study will assess Revita’s efficacy in maintaining weight loss following the discontinuation of its GLP-1 receptor agonist (GLP-1RA) drug therapy. It will enrol patients on tirzepatide who have lost at least 15% of their total body weight.

Tirzepatide, marketed by Eli Lilly as Mounjaro for T2D and Zepbound for the treatment of obesity, is a GLP-1RA therapy.  

The randomised, double-blind trial aims to prove Revita’s superiority over a sham treatment in terms of the percentage change in body weight from baseline to week 24. Additionally, it aims to demonstrate that a majority of patients treated with Revita maintain clinically significant weight loss after stopping tirzepatide. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the announcement accompanying the IDE approval, Brigham and Women’s Hospital endoscopy director Christopher Thompson said: “The unmet need in obesity is shifting from ‘How do we help people lose weight?’ to ‘How do we help people keep the weight off?’” 

Despite receiving IDE approval, Fractyl also delivered disappointing news on 1 April. In its fourth quarter and full-year 2023 earnings report, the company reported a $19.2m net loss for the quarter. This is an increase from a net loss of $10.9m from the same quarter in 2022. 

The biotech remains positive following the announcement.

“2024 is shaping up to be a transformational year as we approach several key milestones across both our Rejuva and Revita platforms,” said Fractyl’s CEO Harith Rajagopalan.